Surrozen, Inc. (NASDAQ:SRZN)
| Market Cap | 237.03M+169.8% |
| Revenue (ttm) | 11.51M-8.8% |
| Net Income | -332.13M-1889.2% |
| EPS | -44.29-218.2% |
| Shares Out | 7.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,704,500.459 |
| Open | 30.57 |
| Previous Close | 16.16 |
| Day's Range | 26.02 - 35.86 |
| 52-Week Range | 11.39 - 35.86 |
| Beta | 0.56 |
| Analysts | Buy |
| Price Target | 44.00(+38.80%) |
| Earnings Date | Nov 6, 2026 |
Surrozen, Inc. has a live Insider Score.
Scored on 0 qualifying trades from 0 insiders in the last 90 days.
About SRZN
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$SRZN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SRZN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SRZN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SRZN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SRZN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SRZN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SRZN
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $6.22M |
| IWMiShares Russell 2000 ETF | $3.03M |
| VXFVanguard Extended Market ETF | $2.27M |
| IWOiShares Russell 2000 Growth ETF | $1.14M |
| VTWOVanguard Russell 2000 ETF | $933.05K |
| IWCiShares Micro-Cap ETF | $396.77K |
Estimated from each fund’s disclosed top holdings × AUM
SRZN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SRZN’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score